纳武利尤单抗联合或不联合伊匹木单抗治疗转移性肉瘤:Alliance A091401两项开放标签非对照随机2期试验
这项多中心开放标签非对照随机2期研究纳入85例晚期/转移性肉瘤患者,比较纳武利尤单抗单药与联合伊匹木单抗的疗效与安全性。主要终点分析显示,单药组确认客观缓解2例(5% [92% CI 1-16]),联合组6例(16% [7-30])。联合治疗在部分亚型中显示 promising 疗效且安全性可控,达到预设主要终点;单药在未选择人群中疗效有限,不建议进一步研究。
要点
- 纳武利尤单抗单药在未选择肉瘤人群中客观缓解率仅5%,疗效有限。
- 纳武利尤单抗联合伊匹木单抗客观缓解率达16%,达到预设主要终点。
- 联合组3级及以上不良事件以贫血(19%)、低血压(10%)较常见,无治疗相关死亡。
核心结论
- 纳武利尤单抗单药在未选择肉瘤人群中疗效有限,不值得进一步研究。
- 纳武利尤单抗联合伊匹木单抗在特定肉瘤亚型中显示 promising 疗效,安全性可控,达到预设主要终点,值得随机研究进一步评估。
研究设计与样本
- 多中心、开放标签、非对照、随机2期研究(Alliance A091401),纳入85例经中心病理确认的晚期/不可切除/转移性肉瘤患者。
- 患者按1:1动态分配至纳武利尤单抗3 mg/kg每2周单药组(43例)或纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg每3周共4次组(42例),此后均接受纳武利尤单抗单药维持至多2年。
- 主要终点为晚期/不可切除/转移性软组织肉瘤确认客观缓解比例,按方案在首批76例可评估患者(每组38例)中分析。
主要发现
- 确认客观缓解:纳武利尤单抗组2例(5% [92% CI 1-16],38例中),联合组6例(16% [7-30],38例中)。
- 纳武利尤单抗组最常见3级及以上不良事件为贫血(4例[10%])、淋巴细胞计数下降(3例[7%]),以及脱水、脂肪酶升高、疼痛、胸腔积液、呼吸衰竭、继发性良性肿瘤、尿路梗阻(各2例[5%])。
- 联合组最常见3级及以上不良事件为贫血(8例[19%])、低血压(4例[10%])、疼痛和尿路感染(各3例[7%])。
- 治疗相关严重不良事件:单药组8例(19%),联合组11例(26%),包括贫血、厌食、脱水、血小板计数下降、腹泻、乏力、发热、肌酐升高、ALT升高、AST升高、低钠血症、疼痛、胸腔积液、瘙痒;无治疗相关死亡。
关键数值与推荐
- 确认客观缓解率:纳武利尤单抗单药组5%(92% CI 1-16),联合组16%(7-30)。
- 联合治疗达到预设主要研究终点。
临床怎么用
- 纳武利尤单抗单药不推荐用于未选择的转移性肉瘤人群。
- 纳武利尤单抗联合伊匹木单抗可作为特定肉瘤亚型的潜在治疗选择,需进一步随机研究验证。
局限性
- 非对照设计,无法直接比较两组间疗效差异。
- 样本量较小(主要分析每组38例),置信区间较宽。
- 未按肉瘤亚型分层报告疗效,特定亚型获益需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. METHODS: We did a multicentre, open-label, non-comparative, randomised, phase 2 study that enrolled patients aged 18 years or older and had central pathology confirmation of sarcoma with at least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, evidence of metastatic, locally advanced or unresectable disease, an ECOG performance status of 0-1, and received at least one previous line of systemic therapy. Patients were assigned to treatment in an unblinded manner, as this trial was conducted as two independent, non-comparative phase 2 trials. Enrolled patients were assigned (1:1) via a dynamic allocation algorithm to intravenous nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses. Thereafter, all patients received nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. The primary endpoint was the proportion of patients with locally advanced, unresectable or metastatic soft tissue sarcoma achieving a confirmed objective response. Analysis was per protocol. This study is ongoing although enrolment is closed. It is registered with ClinicalTrials.gov, number NCT02500797. FINDINGS: Between Aug 13, 2015, and March 17, 2016, 96 patients from 15 sites in the USA underwent central pathology review for eligibility and 85 eligible patients, including planned over-enrolment, were allocated to receive either nivolumab monotherapy (43 patients) or nivolumab plus ipilimumab (42 patients). The primary endpoint analysis was done according to protocol specifications in the first 76 eligible patients (38 patients per group). The number of confirmed responses was two (5% [92% CI 1-16] of 38 patients) in the nivolumab group and six (16% [7-30] of 38 patients) in the nivolumab plus ipilimumab group. The most common grade 3 or worse adverse events were anaemia (four [10%] patients), decreased lymphocyte count (three [7%]), and dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction (two [5%] patients each) among the 42 patients in the nivolumab group and anaemia (eight [19%] patients), hypotension (four [10%] patients), and pain and urinary tract infection (three [7%] patients each) among the 42 patients in the nivolumab plus ipilimumab group. Serious treatment-related adverse events occurred in eight (19%) of 42 patients receiving monotherapy and 11 (26%) of 42 patients receiving combination therapy, and included anaemia, anorexia, dehydration, decreased platelet count, diarrhoea, fatigue, fever, increased creatinine, increased alanine aminotransferase, increased aspartate aminotransferase, hyponatraemia, pain, pleural effusion, and pruritus. There were no treatment-related deaths. INTERPRETATION: Nivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted. FUNDING: Alliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.
引用
- D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018. PMID: 29370992. doi:10.1016/S1470-2045(18)30006-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。